Tevogen Bio Holdings Inc (TVGN) - Total Assets
Based on the latest financial reports, Tevogen Bio Holdings Inc (TVGN) holds total assets worth $4.38 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Tevogen Bio Holdings Inc for net asset value and shareholders' equity analysis.
Tevogen Bio Holdings Inc - Total Assets Trend (2022–2025)
This chart illustrates how Tevogen Bio Holdings Inc's total assets have evolved over time, based on quarterly financial data.
Tevogen Bio Holdings Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Tevogen Bio Holdings Inc's total assets of $4.38 Million consist of 68.2% current assets and 31.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.1% |
| Accounts Receivable | $158.82K | 4.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Tevogen Bio Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TVGN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tevogen Bio Holdings Inc's current assets represent 68.2% of total assets in 2025, a decrease from 93.7% in 2022.
- Cash Position: Cash and equivalents constituted 37.1% of total assets in 2025, down from 93.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 4.6% of total assets.
Tevogen Bio Holdings Inc Competitors by Total Assets
Key competitors of Tevogen Bio Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Tevogen Bio Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.22 | 0.26 | 13.33 |
| Quick Ratio | 0.22 | 0.26 | 13.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.53 Million | $-6.68 Million | $731.82K |
Tevogen Bio Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Tevogen Bio Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 7.05 |
| Asset Growth Rate (YoY) | -37.1% |
| Total Assets | $3.46 Million |
| Market Capitalization | $24.40 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Tevogen Bio Holdings Inc's assets at a significant premium (7.05x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Tevogen Bio Holdings Inc's assets decreased by 37.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tevogen Bio Holdings Inc (2022–2025)
The table below shows the annual total assets of Tevogen Bio Holdings Inc from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $3.46 Million | -37.12% |
| 2024-06-30 | $5.51 Million | -28.86% |
| 2023-06-30 | $7.74 Million | +1.05% |
| 2022-06-30 | $7.66 Million | -- |
About Tevogen Bio Holdings Inc
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 pa… Read more